The global biologics CDMO market continues to surge in 2025 as demand rises for monoclonal antibodies, mRNA, and viral vector manufacturing. These global CDMO capsules spotlight major facility expansions and strategic repositioning efforts by industry leaders.

Capsule 1: Biologics CDMO Market Set to Hit $27B

Strong growth in mAbs, gene therapy, and biosimilars will nearly double the CDMO biologics sector by 2028, according to Research and Markets.

Capsule 2: Samsung Biologics Opens Largest CDMO Plant

Samsung’s Plant 4 in Incheon pushes capacity beyond 600,000L, offering end-to-end solutions for high-volume biologics production.

Capsule 3: Catalent Considers Biologics Spin-off

Catalent announces it may divest portions of its biologics division amid FDA concerns and a company-wide operational review.

Capsule 4: WuXi Biologics Expands in Asia

WuXi unveils new mRNA and ADC manufacturing lines in Singapore and Wuxi to meet global demand and diversify risk outside China.

Internal Link: Explore more biologics news at CDMOworld.com